摘要
目的研究阿帕替尼治疗晚期胃癌的临床疗效。方法回顾性分析98例胃癌患者的临床资料,根据治疗方案不同将其分为实验组和对照组,每组49例。对照组采用替吉奥治疗,实验组在对照组治疗基础上应用甲磺酸阿帕替尼治疗。比较两组临床疗效、不良反应发生情况及治疗前后血清肿瘤标志物水平。结果实验组总有效率为95.92%高于对照组的83.67%,差异具有统计学意义(P<0.05)。实验组不良反应发生率为12.24%,低于对照组的24.49%,差异无统计学意义(P>0.05)。治疗后,实验组糖类抗原199(CA199)、癌胚抗原(CEA)水平分别为(38.22±4.01)U/ml、(4.93±0.65)ng/ml,均低于对照组的(55.53±6.64)U/ml、(8.55±1.05)ng/ml,差异均具有统计学意义(P<0.05)。结论晚期胃癌患者临床治疗期间,在常规用药基础上联合阿帕替尼治疗效果更为显著,可明显降低肿瘤标志物水平,并且不良反应发生率比较低,其安全性较高,值得在临床上进一步推广应用。
Objective To study the clinical efficacy of apatinib in the treatment of advanced gastric cancer.Methods A total of 98 patients with gastric cancer were divided into experimental group and control group according to different treatment regimens,with 49 cases in each group.The control group was treated with tegafur,and the experimental group was treated with apatinib mesylate based on the control group.The clinical efficacy,occurrence of adverse reactions,and serum tumor marker before and after treatment were compared between the two groups.Results The total effective rate 95.92%of the experimental group was higher than 83.67%of the control group,and the difference was statistically significant(P<0.05).The incidence of adverse reactions 12.24%of the experimental group was lower than 24.49%of the control group,but the difference was not statistically significant(P>0.05).After treatment,the levels of carbohydrate antigen 199(CA199)and carcinoembryonic antigen(CEA)of the experimental group were(38.22±4.01)U/ml and(4.93±0.65)ng/ml,which were lower than(55.53±6.64)U/ml and(8.55±1.05)ng/ml of the control group,and the difference was statistically significant(P<0.05).Conclusion During the clinical treatment of patients with advanced gastric cancer,combination of apatinib and routine medication has significant effect on patients with advanced gastric cancer,which can obviously reduce the level of tumor markers,and the incidence of adverse reactions is relatively low.It has high safety and is worthy of further promotion and application in clinical practice.
作者
吴书勇
吴东东
WU Shu-yong;WU Dong-dong(Department of Gastroenterology,Ningjin County People’s Hospital,Dezhou 253400,China)
出处
《中国现代药物应用》
2021年第13期135-137,共3页
Chinese Journal of Modern Drug Application
关键词
阿帕替尼
晚期胃癌
肿瘤标志物
不良反应
Apatinib
Advanced gastric cancer
Tumor markers
Adverse reactions
